Severe Asthma and Nasal Symptoms

Severe Asthma and Nasal Symptoms Related Says Swedish Study

Multi-symptom asthma is closely related to nasal blockage, rhinorrhea and symptoms of chronic rhinosinusitis – evidence from the West Sweden Asthma Study

We have previously shown that approximately 25% of those with asthma in West Sweden have multiple asthma symptoms, which may describe a group of patients with more severe disease. Furthermore, asthma is associated with several co-morbid diseases, including rhinitis and chronic rhino-sinusitis.

The aim of this study was to determine whether multi-symptom asthma is related to signs of severe asthma, and to investigate the association between multi-symptom asthma and different symptoms of allergic and chronic rhinosinusitis.

Methods: This study analyzed data on asthma symptoms, rhinitis, and chronic rhinosinusitis from the 2008 West Sweden Asthma Study, which is an epidemiologically based study using the OLIN and GA2LEN respiratory and allergy focused questionnaires.

Results: Multi-symptom asthma was present in 2.1% of the general population. Subjects with multi-symptom asthma had more than double the risk of having night-time awakenings caused by asthma compared with those with fewer asthma symptoms (P<0.001). The prevalence of allergic rhinitis was similar in the fewer- and multi-symptom asthma groups, but nasal blockage and rhinorrhea were significantly increased in those with multi- versus fewer-symptom asthma (odds ratio 2.21; 95% confidence interval 1.64-2.97, versus 1.49; 1.10-2.02, respectively). Having any, or one to four symptoms of chronic rhinosinusitis significantly increased the risk of having multi- versus fewer-symptom asthma (P<0.01). Conclusion: An epidemiologically identified group of individuals with multiple asthma symptoms harbour to greater extent those with signs of severe asthma. The degree of rhinitis, described by the presence of symptoms of nasal blockage or rhinorrhea, as well as the presence of any or several signs of chronic rhinosinusitis, significantly increases the risk of having multi-symptom asthma. Author: Jan Lotvall Linda Ekerljung Bo Lundback

Landmark Study Shows Suboptimal Asthma Care – Medical News Today (press release)


Babble (blog)

Landmark Study Shows Suboptimal Asthma Care
Medical News Today (press release)
Researchers assessed asthma burden and treatment practice in the US based on results of the recently completed Asthma Insight and Management telephone
Health Alerts: anaphylaxis, recalls, depressionDallas Morning News
Allergic to kissing? Cell phones? Bed Bugs?CNN (blog)
ACAAI: Asthma at Center StageMedPage Today
Rillara News –Medscape –DG News
all 139 news articles »

View full post on asthma – Google News

Chinese Herbs Can Complement Proven Allergy Treatments Herbal Formula Shows … – Newswise (press release)

Chinese Herbs Can Complement Proven Allergy Treatments Herbal Formula Shows
Newswise (press release)
Newswise — Complementary and alternative medicine may give allergy and asthma sufferers new options for treating symptoms, according to allergists at the
Banning Peanuts in Schools and Airplanes Unnecessary: Allergists Can Provide Newswise (press release)
Annual Meeting of the American College of Allergy, Asthma & ImmunologyMedia Newswire (press release)
Plant-based respiratory allergies on the rise due to climate changeNews-Medical.net
Newswise (press release)
all 23 news articles »

View full post on asthma – Google News

Study shows use of corticosteroid inhalers boosts risk of diabetes – Montreal Gazette

Study shows use of corticosteroid inhalers boosts risk of diabetes
Montreal Gazette
Inhaled steroids have become the mainstay of medical treatment of asthma and chronic obstructive pulmonary disease (COPD), the new name for emphysema and
Inhaled steroids may increase the risk of type 2 diabetesEndocrineWeb
Inhaled steroids increase diabetes risk, say Lady Davis Institute researchersEurekAlert (press release)

all 11 news articles »

View full post on asthma – Google News

Quality of Care at U.S. Hospitals Shows Improvement – BusinessWeek


WTNH

Quality of Care at U.S. Hospitals Shows Improvement
BusinessWeek
The care result for children's asthma increased from 70.7 percent in 2007 to 88.1 percent in 2009. The pneumonia care result rose from 72.4 percent in 2002
Quality of care gets better in US hospitalsHealthcare Digital (press release)
Quality of care up at US hospitals, report saysThe Associated Press
Joint Commission Annual Report Shows Big Improvements for Hospital CareMarketwire (press release)
DailyFinance
all 252 news articles »

View full post on asthma – Google News

National Study Shows Drug Effective for Hard-to-Control Asthma – WMTV

Information from the University of Wisconsin Hospital and Clinics:

National Study Shows Drug Effective for Hard-to-Control Asthma

Madison, Wis. – An already available drug eases asthma in patients whose breathing problems persist while using inhaled corticosteroids, according to study results released this week.

University of Wisconsin-Madison researchers who were part of the trial say the ability to prescribe tiotropium bromide – which is already prescribed for chronic obstructive pulmonary disease (COPD) under the brand name Spiriva – adds another weapon to the fight against asthma.

“This is good news because sometimes patients don’t respond to low doses of inhaled corticosteroids, and raising the dose doesn’t always work, either,’’ says Dr. Christine Sorkness, professor of pharmacy at the UW School of Pharmacy. “This gives physicians another option for patients whose asthma is not being adequately controlled.”

Sorkness and Dr. Robert Lemanske, professor of pediatrics and medicine and head of the UW division of pediatric allergy, immunology, and rheumatology at the UW School of Medicine and Public Health, led the UW part of the trial, which enrolled 21 of the 210 adults who took part in the national study. Study results are being released this week in the New England Journal of Medicine and at the Annual Congress of the European Respiratory Society in Barcelona, Spain.

The National Heart, Lung, and Blood Institute (NHLBI) supported the study, which compared three tactics for treating uncontrolled asthma. In one treatment, participants received a doubled dose of inhaled corticosteroids; in the second, inhaled corticosteroids were supplemented by a long-acting beta-agonist (salmeterol); and in the third, the inhaled corticosteroids were supplemented with a long-acting anticholinergic drug (tiotropium bromide). Anticholinergics block the nerves that tighten the muscles around the lungs’ airways whereas beta-agonists relax the muscles lining the breathing passages of the lungs.

Before the trial, the patients averaged 77 days per year when their asthma was under control and they didn’t need to use their albuterol rescue inhalers. Doubling corticosteroids gave patients another 19 symptom-free days on average, while adding tiotropium to low-dose corticosteroids gave them another 48, similar to the improvement they had on corticosteroids plus salmeterol. But increasing corticosteroids and using beta- agonists both have risks,

“This is the first study to explore adding an anticholinergic inhaler to low-dose inhaled corticosteroids,” said Dr. James Kiley, director of the NHLBI’s division of lung diseases. “The Asthma Clinical Research Network is designed to address exactly these kinds of practical and important management questions, with the ultimate goal of helping asthma patients.”

In addition to UW-Madison, other members of the Asthma Clinical Research Network who took part in this trial include: Brigham and Women’s Hospital, Boston; Columbia University, New York City; Duke University, Durham, N.C.; The University of Texas Medical Branch at Galveston; National Jewish Medical and Research Center, Denver; University of California, San Diego; University of California, San Francisco; Washington University School of Medicine, St. Louis; and Wake Forest University. The data coordinating center is at Penn State College of Medicine in Hershey, Pa.